Veterinary Clostridium Vaccine Market Overview
Veterinary Clostridium Vaccine Market Size was valued at USD 0.24 Billion in 2023. The Global Veterinary Clostridium Vaccine industry is projected to grow from USD 0.25 Billion in 2024 to USD 0.36 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.59% during the forecast period (2024 - 2032). The factors such as increased awareness pertaining to zoonotic diseases, the rising incidence rate of clostridium family diseases, increased awareness relating to animal-derived products, and increase in disposable income are expected to propel the growth of the market. However, side effects associated with vaccines and high cost of the treatment hamper the market growth over the forecast period.
Segmentation
The global veterinary clostridium vaccine market has been segmented into animal type, distribution channels, and region.
Based on animal type, the market is segmented into bovine, ovine, swine, caprine, poultry, and others. The bovine segment is expected to account for the largest share segment of the market in 2017.
Based on distribution channels, the market is segmented into veterinary hospital, veterinary clinic, veterinary research institute, and retail pharmacy. The into veterinary hospital segment is expected to account for the largest share segment of the market in 2017.
The market segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The veterinary clostridium vaccine market in the Americas further segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa segmented into the Middle East and Africa.
Regional Market Summary
Global Veterinary Clostridium Vaccine Market Share (%), by Region, 2017
Source: Annual Reports and Sec filings
Geographically, the Americas is anticipated to dominate the global veterinary clostridium vaccine market owing to a well-established player, increased awareness pertaining to zoonotic diseases, rising incidence rate of clostridium family diseases, increased awareness relating animal-derived products, and increase in disposable income.
Europe is expected to hold the second largest position in the global veterinary clostridium vaccine market. The market growth in this region is attributed to increasing awareness about veterinary clostridium vaccine products.
The veterinary clostridium vaccine market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region.
The Middle East & Africa has the least share of the veterinary clostridium vaccine market.
Market Segmentation:By Animal Type
- Bovine
- Ovine
- Swine
- Caprine
- Poultry
- Others
By Distribution Channel
- Veterinary Hospital
- Veterinary Clinic
- Veterinary Research Institute
- Retail Pharmacy
By Region
- Americas
- North America
- Latin America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- The Middle East & Africa
Key Players:
- Merck & Co., Inc. (US)
- Ceva Santé Animale (France)
- Boehringer Ingelheim International GmbH (Germany)
- Colorado Serum Company (US)
- Virbac (Australia)
- Valneva SE (France)
- Zoetis (US)
- Elanco Animal Health (US)
- Bayer AG (Germany)
Intended Audience
- Veterinary Clostridium Vaccine products Manufacturers and vendors
- Research Organization
- Various Research and Consulting Firms
- Veterinary Hospital
- Animal Health Organization and Association
Report Attribute/Metric |
Details |
Market Size |
USD 0.36 Billion |
CAGR |
4.59% |
Base Year |
2023 |
Forecast Period |
2024-2032 |
Historical Data |
2020 |
Forecast Units |
Value (USD Billion) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered |
Animal Type, Distribution Channels and Region |
Geographies Covered |
North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors |
Merck & Co., Inc. (US), Ceva Santé Animale (France), Boehringer Ingelheim International GmbH (Germany), Colorado Serum Company (US), Virbac (Australia), Valneva SE (France), Zoetis (US), Elanco Animal Health (US), Bayer AG (Germany) |
Key Market Opportunities |
· Technological developments· Research & Development activities |
Key Market Drivers |
Increased awareness about zoonotic diseases and rising prevalence of clostridium family diseases are the key factors driving the veterinary clostridium vaccine market. |
Veterinary Clostridium Vaccine Market Highlights:
Frequently Asked Questions (FAQ) :
Veterinary clostridium vaccine market is projected to grow at a 4.59% CAGR between 2024-2032.
The Americas is expected to lead veterinary clostridium vaccine market.
Veterinary hospital segment will dominate the veterinary clostridium vaccine market.
Increased awareness about zoonotic diseases and rising prevalence of clostridium family diseases are the key factors driving the veterinary clostridium vaccine market.
High treatment cost and certain side effects may limit the veterinary clostridium vaccine market growth.